BioRestorative Therapies, a leader in regenerative medicine, has announced encouraging results from its phase 2 clinical trial for BRTX-100, a novel treatment for chronic lumbar disc disease (cLDD). According to CEO Lance Alstodt, the trial demonstrated that over 74% of participants experienced more than a 50% improvement in function, and over 72% reported a greater than 50% reduction in pain, surpassing the FDA's clinically meaningful threshold of 30%.
BRTX-100 represents a significant advancement in the treatment of chronic lower back pain by targeting the root cause of pain rather than merely masking symptoms, as is common with opioids and injectables. The therapy involves harvesting a patient's stem cells, culturing them, and injecting them directly into the affected disc to initiate repair. With the phase 2 trial on track to enroll 99 patients, the company is optimistic about the potential for a pivotal trial or accelerated approval path.
For more details on BioRestorative's innovative approach and future plans, the full interview with Lance Alstodt can be viewed here.
